Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Millendo Therapeutics to Present at Upcoming Investor Conferences


Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, and company management will participate in the following healthcare investor conferences:

32nd Annual ROTH Conference
Panel Presentation
Date and Time: March 16, 2020 at 12:00 p.m. PST
Location: Dana Point, CA

Oppenheimer & Co. 30th Annual Healthcare Conference
Corporate Presentation
Date and Time: March 18, 2020 at 2:45 p.m. EST
Location: New York, NY

A live webcast of the Oppenheimer presentation will be available on the Investors & Media section of Millendo's website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo's website for 30 days following the presentation.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo seeks to create distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.


These press releases may also interest you

at 07:05
Av?sis and Harmony Health Launch Pioneering Salivary Testing Pilot for Patients with Special Healthcare Needs
Av?sis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs. The pilot aims to revolutionize preventive dentistry by harnessing the power of real-time salivary testing...

at 07:05
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
United Therapeutics Corporation , announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately...

at 07:05
Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. , today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development...

at 07:03
Too Much Acid in Your Diet: It's Probably Your Coffee
As more and more consumers search for wellness products, particularly in the area of gut health, recent research from the North Carolina A&T University and existing medical publications confirm that nearly all brewed coffee is a significant source of...

at 07:00
Good Supply Cannabis Introduces New Signature ?Bud Squad' Products
Tilray Brands, Inc. , a leading global cannabis-lifestyle and consumer packaged goods company today announced the release of new cannabis flower products added to the Good Supply® ?Bud Squad'. Good Supply's signature Bud Squad product campaign was...

at 07:00
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
LSL PHARMA GROUP INC. (the "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, today announced the second and final tranche of its private placement financing of Units (as defined hereafter) for $3.8 million representing...

More news about Health...


News published on and distributed by: